Liver cancer is the fourth leading cause of cancer mortality in the world, leading to interest in developing cancer drugs with which to combat the disease. Unfortunately, cost hampers re- search. Drug development costs pharmaceutical companies hun- dreds of millions dollars a year. The cost of development for a single drug was 802 million dollars in the US in 2000 [1]. Part of this cost is related to animal upkeep during stage II drug develop- ment when testing for a drug’s safety. Despite these costs, there is still no assurance that a drug proven safe on animals will also be safe on humans. Differences between the biochemistry of human beings and model organisms can result in differential drug reac- tion. An example is thalidomide which has no teratogenic effect in rats, however, is a potent teratogen in human beings [2]. Given past problems with the use of animals for the safe testing of drugs and other substances, researchers have been motivated to develop in vitro models for drug testing that will not only drive costs down, but will more accurately recapitulate human biochemistry and hence recapitulate human reactions to the drugs tested.